{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:05Z","timestamp":1792552265150,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K08493"],"award-info":[{"award-number":["JP20K08493"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jjcc.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:15:31Z","timestamp":1652746531000},"page":"253-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation"],"prefix":"10.1016","volume":"81","author":[{"given":"Masayoshi","family":"Oikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2022.04.006_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","article-title":"Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia","volume":"20","author":"Tan","year":"1967","journal-title":"Cancer"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0010","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1161\/CIRCRESAHA.121.318223","article-title":"Heart failure with targeted cancer therapies: mechanisms and cardioprotection","volume":"128","author":"Hahn","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12574-020-00502-9","article-title":"Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction","volume":"19","author":"Onishi","year":"2021","journal-title":"J Echocardiogr"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0025","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ehjci\/jex033","article-title":"2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility","volume":"18","author":"Santoro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jcmg.2018.01.015","article-title":"Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction","volume":"11","author":"Zhang","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0040","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0045","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0055","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jjcc.2020.07.014","article-title":"Cardio-Oncology rehabilitation- challenges and opportunities to improve cardiovascular outcomes in cancer patients and survivors","volume":"76","author":"Sase","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review","volume":"2","author":"Bhatia","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","article-title":"Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development","volume":"1132","author":"Capranico","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0080","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0085","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0095","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S","article-title":"Doxorubicin-induced congestive heart failure in adults","volume":"56","author":"Haq","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0100","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0115","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6600346","article-title":"Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients","volume":"86","author":"Nousiainen","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0120","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0125","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.2004.03.516","article-title":"Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial","volume":"22","author":"Perez","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0130","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0135","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0140","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0145","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0150","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096736","article-title":"BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography","volume":"9","author":"Skovgaard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1253\/circj.68.163","article-title":"Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats","volume":"68","author":"Koh","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1179\/102453312X13376952196412","article-title":"Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children","volume":"17","author":"Sherief","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1159\/000507585","article-title":"Cardiac troponin I predicts elevated B-type natriuretic peptide in patients treated with anthracycline-containing chemotherapy","volume":"98","author":"Oikawa","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jjcc.2020.10.007","article-title":"Early electrocardiographic indices for predicting chronic doxorubicin-induced cardiotoxicity","volume":"77","author":"Kinoshita","year":"2021","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0185","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0190","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0195","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0200","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0210","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1083\/jcb.200504124","article-title":"FAK signaling is critical for ErbB-2\/ErbB-3 receptor cooperation for oncogenic transformation and invasion","volume":"171","author":"Benlimame","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0220","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0225","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0230","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/378386a0","article-title":"Multiple essential functions of neuregulin in development","volume":"378","author":"Meyer","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0235","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0240","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0245","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","article-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis","volume":"37","author":"Chen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0250","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0255","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamacardio.2019.5586","article-title":"Long-term cardiopulmonary consequences of treatment-induced cardiotoxicity in survivors of ERBB2-positive breast cancer","volume":"5","author":"Yu","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE Study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0265","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0270","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: Where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0275","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0280","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"Celutkiene","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0285","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0290","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0295","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","article-title":"Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy +\/- trastuzumab","volume":"37","author":"Gujral","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0310","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169964","article-title":"A novel positron emission tomography (PET) approach to monitor cardiac metabolic pathway remodeling in response to sunitinib malate","volume":"12","author":"O\u2019Farrell","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2019.152281","article-title":"Mitochondrial oxidative stress plays a critical role in the cardiotoxicity of sunitinib: running title: sunitinib and oxidative stress in hearts","volume":"426","author":"Bouitbir","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0330","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0335","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","article-title":"Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib","volume":"29","author":"Richards","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0340","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0345","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0350","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0355","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0360","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0365","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0370","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004408","article-title":"Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Catino","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0375","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jjcc.2019.09.019","article-title":"The critical roles of protein quality control systems in the pathogenesis of heart failure","volume":"75","author":"Maejima","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0380","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0385","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0390","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0400","first-page":"1016","article-title":"Revisiting the hallmarks of cancer","volume":"7","author":"Fouad","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0405","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology Primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0410","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0415","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0420","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0425","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.006_bb0430","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1335","key":"10.1016\/j.jjcc.2022.04.006_bb0435","article-title":"Progressive and reversible conduction disease with checkpoint inhibitors","volume":"33","author":"Reddy","year":"2017","journal-title":"Can J Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:07:30Z","timestamp":1760274450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508722000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0914508722000946"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.04.006","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}